CSL (CSL) Share Forecast & Price Target

Compare

556 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CSL Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

CSL

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CSL Stock 12 Month Forecast

Average Price Target

AU$306.79

▲(19.20%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for CSL in the last 3 months. The average price target is AU$306.79 with a high forecast of AU$329.93 and a low forecast of AU$282.94. The average price target represents a 19.20% change from the last price of AU$257.38.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"237":"AU$237","330":"AU$330","260.25":"AU$260.3","283.5":"AU$283.5","306.75":"AU$306.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":329.9259558550725,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$329.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":306.7922124645,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$306.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":282.9365015363197,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$282.94</span>\n  </div></div>","useHTML":true}}],"tickPositions":[237,260.25,283.5,306.75,330],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,238.24,245.29276583500558,252.34553167001116,259.3982975050167,266.4510633400223,273.5038291750279,280.55659501003345,287.6093608450391,294.66212668004465,301.7148925150502,308.7676583500558,315.82042418506137,322.87319002006694,{"y":329.9259558550725,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,238.24,243.51324711265386,248.7864942253077,254.05974133796155,259.3329884506154,264.60623556326925,269.8794826759231,275.15272978857695,280.42597690123074,285.6992240138846,290.97247112653844,296.2457182391923,301.51896535184613,{"y":306.7922124645,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,238.24,241.67819242587075,245.11638485174151,248.55457727761225,251.992769703483,255.43096212935376,258.8691545552245,262.30734698109524,265.745539406966,269.1837318328367,272.6219242587075,276.06011668457825,279.498309110449,{"y":282.9365015363197,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":288.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":305.92,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":301.143,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.921,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":279.384,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.402,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":279.344,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.203,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":258.501,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":251.57,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":251.12,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":247.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":238.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetAU$329.93

Average Price TargetAU$306.79

Lowest Price TargetAU$282.94

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

AU$275

Hold

6.85%

Upside

Reiterated

07/16/25

CSL's strong financial performance and positive earnings call sentiment highlight its robust position in the biotechnology sector. However, valuation concerns and technical indicators suggest cautious optimism due to market pricing and potential volatility.

Laura SutcliffeUBS

UBS

AU$310

Buy

20.44%

Upside

Reiterated

07/18/25

CSL (CMXHF) Receives a Buy from UBS

Craig Wong-PanRBC Capital

RBC Capital

AU$279→AU$283

Hold

9.95%

Upside

Reiterated

07/16/25

RBC Capital Sticks to Their Hold Rating for CSL (CMXHF)

Derek JellinekMorgans

Morgans

AU$303

Buy

17.72%

Upside

Reiterated

07/10/25

CSL (CMXHF) Gets a Buy from Morgans

Steven WheenJarden

Jarden

AU$317.61→AU$313.12

Buy

21.66%

Upside

Reiterated

07/09/25

CSL (CMXHF) Gets a Buy from Jarden

Andrew PaineCLSA

CLSA

AU$330

Buy

28.22%

Upside

Reiterated

06/24/25

CLSA Sticks to Their Buy Rating for CSL (CMXHF)

Thomas WakimBell Potter

Bell Potter

AU$305

Buy

18.50%

Upside

Reiterated

06/22/25

Bell Potter Sticks to Its Buy Rating for CSL (CMXHF)

Unknown AnalystOrd Minnett

Not Ranked

Ord Minnett

AU$310

Buy

20.44%

Upside

Reiterated

06/20/25

Ord Minnett Sticks to Their Buy Rating for CSL (CMXHF)

David BaileyMorgan Stanley

Morgan Stanley

AU$313→AU$303

Buy

17.72%

Upside

Reiterated

06/18/25

Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (Other OTC: CSBTF), CSL (Other OTC: CMXHF) and Roche Holding AG (Other OTC: RHHVF)

Davinthra ThillainathanGoldman Sachs

Goldman Sachs

AU$307.2→AU$304.6

Buy

18.35%

Upside

Reiterated

05/13/25

CSL (CMXHF) Gets a Buy from Goldman Sachs

David StantonJefferies

Jefferies

AU$333→AU$320

Buy

24.33%

Upside

Reiterated

04/16/25

Jefferies Keeps Their Buy Rating on CSL (CMXHF)

David LowJ.P. Morgan

J.P. Morgan

AU$325→AU$315

Buy

22.39%

Upside

Reiterated

02/12/25

CSL Ltd. (CSL:AU) (CMXHF) PT Lowered to AUD315 at JPMorganJPMorgan analyst David Low lowered the price target on CSL Ltd. (CSL:AU) (OTC: CMXHF) to AUD315.00 (from AUD325.00) while maintaining a Overweight rating.

Shane StoreyWilsons

Wilsons

AU$250

Hold

-2.87%

Downside

Reiterated

02/11/25

Wilsons Sticks to Their Hold Rating for CSL (CMXHF)

Christine TrinhMacquarie

Macquarie

AU$334→AU$360.3

Buy

39.99%

Upside

Reiterated

02/11/25

Macquarie Reiterates Outperform Rating on CSL Ltd. (CSL:AU) (CMXHF)Macquarie analyst Christine Trinh reiterated an Outperform rating and AUD360.30 price target on CSL Ltd. (CSL:AU) (OTC: CMXHF).

Mathieu ChevrierCiti

Citi

AU$345→AU$335

Buy

30.16%

Upside

Reiterated

02/11/25

Citi Reaffirms Their Buy Rating on CSL (CMXHF)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

AU$275

Hold

6.85%

Upside

Reiterated

07/16/25

Laura SutcliffeUBS

UBS

AU$310

Buy

20.44%

Upside

Reiterated

07/18/25

CSL (CMXHF) Receives a Buy from UBS

Craig Wong-PanRBC Capital

RBC Capital

AU$279→AU$283

Hold

9.95%

Upside

Reiterated

07/16/25

RBC Capital Sticks to Their Hold Rating for CSL (CMXHF)

Derek JellinekMorgans

Morgans

AU$303

Buy

17.72%

Upside

Reiterated

07/10/25

CSL (CMXHF) Gets a Buy from Morgans

Steven WheenJarden

Jarden

AU$317.61→AU$313.12

Buy

21.66%

Upside

Reiterated

07/09/25

CSL (CMXHF) Gets a Buy from Jarden

Andrew PaineCLSA

CLSA

AU$330

Buy

28.22%

Upside

Reiterated

06/24/25

CLSA Sticks to Their Buy Rating for CSL (CMXHF)

Thomas WakimBell Potter

Bell Potter

AU$305

Buy

18.50%

Upside

Reiterated

06/22/25

Bell Potter Sticks to Its Buy Rating for CSL (CMXHF)

Unknown AnalystOrd Minnett

Not Ranked

Ord Minnett

AU$310

Buy

20.44%

Upside

Reiterated

06/20/25

Ord Minnett Sticks to Their Buy Rating for CSL (CMXHF)

David BaileyMorgan Stanley

Morgan Stanley

AU$313→AU$303

Buy

17.72%

Upside

Reiterated

06/18/25

Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (Other OTC: CSBTF), CSL (Other OTC: CMXHF) and Roche Holding AG (Other OTC: RHHVF)

Davinthra ThillainathanGoldman Sachs

Goldman Sachs

AU$307.2→AU$304.6

Buy

18.35%

Upside

Reiterated

05/13/25

CSL (CMXHF) Gets a Buy from Goldman Sachs

David StantonJefferies

Jefferies

AU$333→AU$320

Buy

24.33%

Upside

Reiterated

04/16/25

Jefferies Keeps Their Buy Rating on CSL (CMXHF)

David LowJ.P. Morgan

J.P. Morgan

AU$325→AU$315

Buy

22.39%

Upside

Reiterated

02/12/25

Shane StoreyWilsons

Wilsons

AU$250

Hold

-2.87%

Downside

Reiterated

02/11/25

Wilsons Sticks to Their Hold Rating for CSL (CMXHF)

Christine TrinhMacquarie

Macquarie

AU$334→AU$360.3

Buy

39.99%

Upside

Reiterated

02/11/25

Macquarie Reiterates Outperform Rating on CSL Ltd. (CSL:AU) (CMXHF)Macquarie analyst Christine Trinh reiterated an Outperform rating and AUD360.30 price target on CSL Ltd. (CSL:AU) (OTC: CMXHF).

Mathieu ChevrierCiti

Citi

AU$345→AU$335

Buy

30.16%

Upside

Reiterated

02/11/25

Citi Reaffirms Their Buy Rating on CSL (CMXHF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CSL

1 Month

xxx

Success Rate

8/15 ratings generated profit

Average Return

-1.75%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of -1.75% per trade.

3 Months

xxx

Success Rate

6/12 ratings generated profit

Average Return

+2.27%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +2.27% per trade.

1 Year

David BaileyMorgan Stanley

Success Rate

7/12 ratings generated profit

Average Return

+1.20%

reiterated a buy rating last month

Copying David Bailey's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +1.20% per trade.

2 Years

xxx

Success Rate

6/12 ratings generated profit

Average Return

-1.00%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -1.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CSL Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CSL has received 12 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. CSL average Analyst price target in the past 3 months is 306.79.

Each month's total comprises the sum of three months' worth of ratings.

CSL Financial Forecast

CSL Earnings Forecast

Next quarter’s earnings estimate for CSL is AU$4.29 with a range of AU$3.37 to AU$6.81. The previous quarter’s EPS was AU$6.59. CSL beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year CSL has Preformed in-line its overall industry.

CSL Sales Forecast

Next quarter’s sales forecast for CSL is AU$10.99B with a range of AU$10.31B to AU$11.43B. The previous quarter’s sales results were AU$12.75B. CSL beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year CSL has Preformed in-line its overall industry.

CSL Stock Forecast FAQ

What is AU:CSL’s average 12-month price target, according to analysts?

Based on analyst ratings, CSL’s 12-month average price target is 306.79.

What is AU:CSL’s upside potential, based on the analysts’ average price target?

CSL has 19.20% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CSL a Buy, Sell or Hold?

CSL has a consensus rating of Strong Buy, which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is CSL’s share price target?

The average share price target for CSL is 306.79. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is AU$329.93 ,and the lowest forecast is AU$282.94. The average share price target represents 19.20% Increase from the current price of AU$257.38.

What do analysts say about CSL?

CSL’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of CSL?

To buy shares of AU:CSL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

CSL (CSL) Share Forecast & Price Target

CSL Analyst Ratings

CSL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering CSL

CSL Analyst Recommendation Trends

CSL Financial Forecast

CSL Earnings Forecast

CSL Sales Forecast

CSL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts